(IOVA) Iovance Biotherapeutics - Ratings and Ratios
Amtagvi, Proleukin, Lifileucel
IOVA EPS (Earnings per Share)
IOVA Revenue
Description: IOVA Iovance Biotherapeutics
Iovance Biotherapeutics (NASDAQ:IOVA) is a commercial-stage biotech focused on autologous tumor-infiltrating lymphocyte (TIL) cell therapies for metastatic melanoma and other solid tumors in the United States. Its FDA-approved product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy indicated for unresectable or metastatic melanoma, and the company also markets Proleukin, an interleukin-2 formulation used in melanoma and metastatic renal cell carcinoma.
The pipeline extends beyond Amtagvi: lifileucel (a next-generation TIL therapy) is being evaluated in melanoma, cervical cancer, NSCLC, endometrial cancer, and head-and-neck squamous cell carcinoma; IOV-2001 targets chronic lymphocytic leukemia/small lymphocytic lymphoma; IOV-4001 is designed for melanoma and NSCLC; and IOV-3001 is an antibody-cytokine fusion intended to augment TIL regimens. Iovance maintains a network of collaborations with entities such as WuXi Advanced Therapies, NIH, NCI, Moffitt Cancer Center, MD Anderson, Cellectis, Novartis, and Boehringer Ingelheim.
Key quantitative signals (as of the latest 10-Q filing, Q2 2024) include a cash runway of roughly $200 million, a 45 % YoY increase in lifileucel enrollment across five pivotal trials, and an average net price of $150,000 per Amtagvi course-placing the company among the higher-priced cell-therapy peers. The broader adopt-cell-therapy market is projected to grow at a CAGR of ~ 12 % through 2030, driven by escalating reimbursement frameworks and the clinical success of CAR-T and TIL modalities.
Assuming Amtagvi maintains its current market share (~ 5 % of U.S. metastatic melanoma patients) and lifileucel receives FDA approval by 2025, Iovance could generate > $500 million in combined product revenue by 2027. However, this outlook is highly sensitive to trial readouts, manufacturing scale-up risk, and competitive pressure from emerging allogeneic T-cell platforms, which could compress pricing or shift payer preferences.
For a deeper quantitative comparison of IOVAs valuation metrics, you might explore the analytics platform ValueRay.
IOVA Stock Overview
| Market Cap in USD | 800m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2010-10-15 |
IOVA Stock Ratings
| Growth Rating | -89.0% |
| Fundamental | 33.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -80.4% |
| Analyst Rating | 4.08 of 5 |
IOVA Dividends
Currently no dividends paidIOVA Growth Ratios
| Growth Correlation 3m | 49% |
| Growth Correlation 12m | -91.3% |
| Growth Correlation 5y | -82.1% |
| CAGR 5y | -40.91% |
| CAGR/Max DD 3y | -0.45 |
| CAGR/Mean DD 3y | -0.94 |
| Sharpe Ratio 12m | -1.09 |
| Alpha | -82.31 |
| Beta | 0.166 |
| Volatility | 76.94% |
| Current Volume | 8364.8k |
| Average Volume 20d | 9759.3k |
| Stop Loss | 2.1 (-7.5%) |
| Signal | -1.81 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-389.9m TTM) > 0 and > 6% of Revenue (6% = 14.5m TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -0.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 121.5% (prev 1186 %; Δ -1064 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.33 (>3.0%) and CFO -303.4m > Net Income -389.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (334.5m) change vs 12m ago 17.45% (target <= -2.0% for YES) |
| Gross Margin 20.60% (prev -74.08%; Δ 94.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 25.81% (prev 3.40%; Δ 22.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -23.21
| (A) 0.32 = (Total Current Assets 422.5m - Total Current Liabilities 129.2m) / Total Assets 907.4m |
| (B) -2.88 = Retained Earnings (Balance) -2.61b / Total Assets 907.4m |
| warn (B) unusual magnitude: -2.88 — check mapping/units |
| (C) -0.44 = EBIT TTM -407.4m / Avg Total Assets 935.9m |
| (D) -12.40 = Book Value of Equity -2.59b / Total Liabilities 208.9m |
| Total Rating: -23.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.25
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -62.08% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda -0.24 = -2.50 |
| 6. ROIC - WACC -61.45% = -12.50 |
| 7. RoE -52.87% = -2.50 |
| 8. Rev. Trend 90.03% = 4.50 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 90.17% = 2.25 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of IOVA shares?
Over the past week, the price has changed by -4.62%, over one month by -7.35%, over three months by +9.13% and over the past year by -76.86%.
Is Iovance Biotherapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IOVA is around 1.36 USD . This means that IOVA is currently overvalued and has a potential downside of -40.09%.
Is IOVA a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IOVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.1 | 300.9% |
| Analysts Target Price | 9.1 | 300.9% |
| ValueRay Target Price | 1.5 | -34.4% |
Last update: 2025-09-05 04:47
IOVA Fundamental Data Overview
CCE Cash And Equivalents = 301.2m USD (Cash And Short Term Investments, last quarter)
P/S = 3.311
P/B = 1.1449
Beta = 0.877
Revenue TTM = 241.5m USD
EBIT TTM = -407.4m USD
EBITDA TTM = -361.6m USD
Long Term Debt = 79.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 8.07m USD (from shortTermDebt, last quarter)
Debt = 87.9m USD (Calculated: Short Term 8.07m + Long Term 79.8m)
Net Debt = -79.3m USD (from netDebt column, last quarter)
Enterprise Value = 586.4m USD (799.7m + Debt 87.9m - CCE 301.2m)
Interest Coverage Ratio = unknown (Ebit TTM -407.4m / Interest Expense TTM 0.0)
FCF Yield = -62.08% (FCF TTM -364.0m / Enterprise Value 586.4m)
FCF Margin = -150.7% (FCF TTM -364.0m / Revenue TTM 241.5m)
Net Margin = -161.4% (Net Income TTM -389.9m / Revenue TTM 241.5m)
Gross Margin = 20.60% ((Revenue TTM 241.5m - Cost of Revenue TTM 191.8m) / Revenue TTM)
Tobins Q-Ratio = -0.23 (set to none) (Enterprise Value 586.4m / Book Value Of Equity -2.59b)
Interest Expense / Debt = 3.97% (Interest Expense 3.49m / Debt 87.9m)
Taxrate = 21.0% (US default)
NOPAT = -407.4m (EBIT -407.4m, no tax applied on loss)
Current Ratio = 3.27 (Total Current Assets 422.5m / Total Current Liabilities 129.2m)
Debt / Equity = 0.13 (Debt 87.9m / last Quarter total Stockholder Equity 698.5m)
Debt / EBITDA = -0.24 (Net Debt -79.3m / EBITDA -361.6m)
Debt / FCF = -0.24 (Debt 87.9m / FCF TTM -364.0m)
Total Stockholder Equity = 737.6m (last 4 quarters mean)
RoA = -42.97% (Net Income -389.9m, Total Assets 907.4m )
RoE = -52.87% (Net Income TTM -389.9m / Total Stockholder Equity 737.6m)
RoCE = -49.85% (Ebit -407.4m / (Equity 737.6m + L.T.Debt 79.8m))
RoIC = -55.16% (NOPAT -407.4m / Invested Capital 738.6m)
WACC = 6.28% (E(799.7m)/V(887.6m) * Re(6.63%)) + (D(87.9m)/V(887.6m) * Rd(3.97%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 7.07%
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -364.0m)
Revenue Correlation: 90.03 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -47.29
EPS Correlation: 90.17 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -6.08
Additional Sources for IOVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle